QRL-204 is a splice-switching ASO generated through QurAlis’ FlexASO™ Platform; represents Lilly’s first program targeting UNC13A in ALS and FTD
Parties to also collaborate to leverage QurAlis’ ALS and ASO development expertise to advance QRL-204 and next-generation compounds
UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases
CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ — QurAlis Corporation (“QurAlis”) today announced that it has entered into an exclusive license agreement with Eli Lilly and Company (“Lilly”) in which QurAlis is granting Lilly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.
